No discrete molecular target – effects mediated via secreted factors and cell–cell interactions

The designation "No discrete molecular target – effects mediated via secreted factors and cell–cell interactions" is a classification used in pharmacological databases like ChEMBL to describe therapeutic agents, primarily cell-based therapies, that do not interact with a single, specific molecular receptor or enzyme (ChEMBL, 2024). Instead, these therapies exert their biological effects through a multi-modal mechanism involving the release of a complex secretome—comprising cytokines, chemokines, and growth factors—and direct physical contact with host cells to modulate the local or systemic environment (PubMed, PMID: 31034648). This approach is central to regenerative medicine and advanced immunotherapies, where the goal is to orchestrate a broad physiological response, such as tissue repair or immune suppression, rather than inhibiting a specific pathway (StatPearls, 2023). Because the "target" is a functional outcome of complex biological interactions rather than a discrete protein, these agents present unique challenges for traditional pharmacokinetic modeling and regulatory standardization (NIH, 2022). This classification highlights the shift from the traditional one-drug-one-target paradigm toward holistic, systems-based therapeutic interventions (Nature Reviews Drug Discovery, 2021).

Other names

Non-specific cellular targetCell-mediated therapy mechanismParacrine and juxtacrine signaling effectsSecretome-mediated mechanism

Modulation of the host microenvironment through the collective action of secreted cytokines, growth factors, and extracellular vesicles (paracrine signaling) alongside direct physical interactions between therapeutic and endogenous cells (juxtacrine signaling).